Human Longevity Appoints Dr. David Karow, M.D., Ph.D., As Interim Chief Executive Officer, Invigorating Company's Vision To Drive Health Intelligence

Leadership Team Refined and Strengthened

Human Longevity, Inc. (HLI), the genomics-powered, health intelligence company, announced today that David Karow M.D., Ph.D., has been appointed Interim Chief Executive Officer by the company's Board of Directors.

Serving most recently as HLI's Chief of Radiogenomics, Dr. Karow has been a guiding force behind the company's signature clinical research and discovery center, Health Nucleus, which infuses genomics and advanced imaging into traditional healthcare for a more proactive and preventative approach. Dr. Karow has also focused on developing machine learning-based integrated diagnostics of chronic age-related disease.

Dr. Karow will partner with Scott Sorensen, HLI's Chief Technology Officer, who will also assume the responsibilities of Interim Chief Operations Officer. Sorensen joined the company earlier this year from Ancestry to refine HLI's focus on delivering a state-of-the-art customer experience and patient friendly products.

Together Karow and Sorensen will oversee HLI's business strategy incorporating genomic analytics, machine learning and advanced clinical imaging poised to yield tremendous impact to benefit HLI's customers and the broader scientific field.

Dr. Karow joined HLI following two decades of research, clinical practice and training at University of California San Diego, University of California Los Angeles and the University of Michigan, Ann Arbor driving advancements to optimize clinical imaging and more recently the integration with genetics.

Dr. Karow has been integral to the development and expansion strategy of the Health Nucleus. He has led key strategic partnerships related to the center's technology and analysis and has steered the development of groundbreaking reports focusing on several key areas that are the primary causes of premature death: cancer detection, cardiac disease, metabolic disease and neurodegenerative and neurovascular disease.

"I believe so strongly in the work Human Longevity and the Health Nucleus has done and the team we have built, and I'm thrilled to engage in this new role to help realize what we have set out to do," said Dr. David Karow. "We've just scratched the surface of identifying the hallmarks of, and delivering with great success, data-driven precision healthcare guided by genomic analytics. And as an organization, in partnership with the Board, I am eager to see what more we can do."

About Human Longevity, Inc.™

Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines its database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI's business focus includes the HLI Health Nucleus, a genomic-powered, clinical research and discovery center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com.

SOURCE Human Longevity, Inc.

CONTACT: Katie McCormick Lelyveld, 312-533-1038, kml@humanlongevity.com